Janus Henderson Group’s Contineum Therapeutics CTNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.1M Buy
+1,723,312
New +$25.7M 0.01% 604
2026
Q1
$35.6M Buy
2,734,836
+285,857
+12% +$3.83M 0.02% 472
2025
Q4
$27.9M Buy
+2,448,979
New +$27.9M 0.01% 529
2025
Q2
– Sell
-42,499
Closed -$300K – 2514
2025
Q1
$300K Sell
42,499
-25,821
-38% -$235K ﹤0.01% 2204
2024
Q4
$1M Buy
+68,320
New +$1.08M ﹤0.01% 1685

Other funds holding CTNM

Janus Henderson Group's CTNM Position: Q3 2026 in Review

Janus Henderson Group opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 1,723,312 shares worth $23.1M. The stake represents 0.01% of the portfolio and ranks #604 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in CTNM as recently as Q1 2026.

Janus Henderson Group first reported a position in CTNM in Q4 2024 and has held it in 5 quarters since. The position peaked at $35.6M in Q1 2026. 110 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Janus Henderson Group held 1,723,312 shares of Contineum Therapeutics worth $23.1M as of Q3 2026.
  • Contineum Therapeutics was a new Janus Henderson Group position in Q3 2026.
  • Contineum Therapeutics made up 0.01% of Janus Henderson Group's portfolio in Q3 2026, its #604 holding.
  • Janus Henderson Group first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Janus Henderson Group's Contineum Therapeutics position peaked at $35.6M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.